- Home
- Publications
- Publication Search
- Publication Details
Title
PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-06-04
DOI
10.3389/fimmu.2019.01242
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MiR-873/PD-L1 axis regulates the stemness of breast cancer cells
- (2019) Lanlan Gao et al. EBioMedicine
- PD-1 is expressed by and regulates human group 3 innate lymphoid cells in human decidua
- (2019) Paola Vacca et al. Mucosal Immunology
- PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy
- (2019) Arash Salmaninejad et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors: Functional analysis and expression of PD‐1 receptor
- (2019) Nicola Tumino et al. INTERNATIONAL JOURNAL OF CANCER
- Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading
- (2019) Jeremy Force et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Immune suppression by PD-L2 against spontaneous and treatment-related antitumor immunity
- (2019) Hiroyoshi Nishikawa et al. CLINICAL CANCER RESEARCH
- PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
- (2018) Haidong Tang et al. JOURNAL OF CLINICAL INVESTIGATION
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
- (2018) Fei Tang et al. Cell and Bioscience
- TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
- (2018) Alice L. Hung et al. OncoImmunology
- Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
- (2018) Joy Hsu et al. JOURNAL OF CLINICAL INVESTIGATION
- Endogenous glucocorticoids control host resistance to viral infection through the tissue-specific regulation of PD-1 expression on NK cells
- (2018) Linda Quatrini et al. NATURE IMMUNOLOGY
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer
- (2018) SHINKICHI TAKAMORI et al. ANTICANCER RESEARCH
- Expression of programmed cell death ligand 1 in non-small cell lung cancer: Comparison between cytologic smears, core biopsies, and whole sections using the SP263 assay
- (2018) Enrico Munari et al. CANCER CYTOPATHOLOGY
- Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
- (2018) Pascale André et al. CELL
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- New miRNA Signature Heralds Human NK Cell Subsets at Different Maturation Steps: Involvement of miR-146a-5p in the Regulation of KIR Expression
- (2018) Silvia Pesce et al. Frontiers in Immunology
- PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression
- (2018) Francesca R. Mariotti et al. OncoImmunology
- Immunotherapy for Head and Neck Cancer
- (2018) Felix Sim et al. Oral and Maxillofacial Surgery Clinics of North America
- Tim-3 and its role in regulating anti-tumor immunity
- (2017) Madhumita Das et al. IMMUNOLOGICAL REVIEWS
- Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization
- (2017) Silvia Pesce et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
- (2017) Hans J. Hammers et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune checkpoints on innate lymphoid cells
- (2017) Laura Chiossone et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-1 regulates KLRG1+group 2 innate lymphoid cells
- (2017) Samuel Taylor et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers
- (2017) Y Liu et al. ONCOGENE
- Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
- (2017) Janet Lau et al. Nature Communications
- Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
- (2017) Takuro Noguchi et al. Cancer Immunology Research
- PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
- (2017) Jan Willem Kleinovink et al. OncoImmunology
- Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy
- (2016) S. J. Blake et al. CLINICAL CANCER RESEARCH
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy
- (2016) S. J. Blake et al. Cancer Discovery
- PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma
- (2016) Asma Beldi-Ferchiou et al. Oncotarget
- Features of Memory-Like and PD-1+ Human NK Cell Subsets
- (2016) Mariella Della Chiesa et al. Frontiers in Immunology
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cancer risk in relatives of patients with a primary disorder of lymphocyte cytotoxicity: a retrospective cohort study
- (2015) Alexandra Löfstedt et al. Lancet Haematology
- B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape
- (2015) Silvia Pesce et al. OncoImmunology
- CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
- (2014) Yu-Hwa Huang et al. NATURE
- Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
- (2014) I. P. da Silva et al. Cancer Immunology Research
- TLR/NCR/KIR: Which One to Use and When?
- (2014) Simona Sivori et al. Frontiers in Immunology
- Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
- (2013) H. E. Kohrt et al. BLOOD
- A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
- (2012) N. Vey et al. BLOOD
- Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
- (2012) Shigeki Chiba et al. NATURE IMMUNOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Melanoma drug wins US approval
- (2011) Heidi Ledford NATURE
- Innate or Adaptive Immunity? The Example of Natural Killer Cells
- (2011) E. Vivier et al. SCIENCE
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation
- (2010) L. Moretta et al. BLOOD
- PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1
- (2010) M. Ghiotto et al. INTERNATIONAL IMMUNOLOGY
- Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells
- (2009) F. Romagne et al. BLOOD
- Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation
- (2009) M. Nakayama et al. BLOOD
- Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia
- (2008) Luc Xerri et al. HUMAN PATHOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started